ClinicalTrials.gg
RecruitingNCT07140523Updated Jan 15, 2026

A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA

A Phase 2 interventional study of SRSD107 and enoxaparin in Venous Thromboembolism, sponsored by Sirius Therapeutics Co., Ltd.. Recruiting at 1 site in Czechia. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Sirius Therapeutics Co., Ltd. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Venous Thromboembolism with a site in Czechia — 2 open to participants now, 2 under way, none of them phase 3. Venous Thromboembolism · Czechia.

Planned enrollment
22nd of 29
450 · median 1,150
Started
2025
the only one that year
Phase 2
5 of 34
1 open now
Registered
34th of 34
by date

Among the 34 studies in Venous Thromboembolism with a site in Czechia, this one is the 22nd largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 34th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 34 studies in Venous Thromboembolism with a site in Czechia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Venous Thromboembolism with a site in Czechia, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA.

Read the detailed description

This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA. While the identity of the study drug will be unblinded, the specific dose of SRSD107 will be blinded. Up to approximately 450 subjects will be randomized.

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written before any study assessment is performed.
  2. Male and female subjects, of any race, between 60 and 80 years of age, inclusive.
  3. between 18.0 and 35.0 kg/m2, inclusive.
  4. Eligible to undergo elective primary unilateral TKA under general anesthesia.
  5. Willing to comply with study requirements including taking study drug at least 28 days prior to TKA, clinic visits, and venography at 10-14 days post TKA.
  6. , PT, and INR within the normal reference range at screening.

Exclusion criteria

Exclusion Criteria:

  1. Active bleeding requiring medical or surgical intervention within 4 weeks prior to screening.
  2. Known bleeding disorder; history of increased bleeding tendency or any other condition that in the opinion of the investigator contraindicates prophylactic anticoagulation.
  3. History of intracranial, intraspinal, or intraocular bleeding.
  4. Evidence of active cancer, or a history of , within 2 years prior to screening.
  5. Myocardial infarction, DVT, PE, stroke , , systemic embolism, valvular thrombosis, or splanchnic thrombosis in the 6 months prior to screening.
  6. Uncontrolled blood pressure at the time of screening.
  7. Estimated (eGFR) \< 45 mL/min/1.73m2.
  8. Liver dysfunction, liver cirrhosis, history of hepatic encephalopathy, esophageal varices, or portocaval shunt.
  9. anemia at screening.
  10. counts \<100,000/m3 at screening or a history of heparin-induced thrombocytopenia.
  11. Positive test for (HIV) , positive surface antigen, and/or active at screening.
  12. Ongoing or anticipated need for anticoagulation or antiplatelet therapy from 7 days prior to surgery through the EoS visit.
  13. Participation in an interventional clinical study within 5 half-lives of the drug or 30 days prior to screening, whichever is longer.
  14. Use of any ASO or siRNA products within 1 year prior to screening. Diet and Lifestyle.
  15. Recent or current history of alcoholism or recreational drug abuse.
  16. History of to any of the study drugs or its , to drugs of similar chemical classes or drugs issued from the same biologic origin or any listed in the label for enoxaparin.
  17. Unable to undergo venography due to a known allergy to the contrast agent, anticipated poor venous access, impaired renal function, or any other reason identified and specified by the investigator.
  18. Anticipated elective surgery during the study period.
  19. Any other condition or circumstance that would affect the subject's ability to be compliant with study drug administration or study procedures, in the opinion of the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    SRSD107 low dose

    Cohort 1: SRSD107, low dose level, subcutaneous (s.c.), single dose

    Drug: SRSD107

  • Experimental
    SRSD107 medium dose

    Cohort 2: SRSD107, medium dose level, subcutaneous (s.c.), single dose

    Drug: SRSD107

  • Experimental
    SRSD107 high dose

    Cohort 3: SRSD107, high dose level, subcutaneous (s.c.), single dose

    Drug: SRSD107

  • Active comparator
    Enoxaparin

    Cohort 4: Enoxaparin 40 mg s.c., once a day (q.d.), 12 ±2 days post-surgery

    Drug: enoxaparin

Interventions

  • SRSD107 is an investigational siRNA product for anticoagulants.

  • Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.

    Also known as: Clexane, Lovenox

06

What researchers measure

Primary outcomes

  1. Incidence of total venous thromboembolism (VTE) events

    Defined as deep vein thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), non-fatal and fatal PE, and unexplained death for which PE cannot be excluded.

    Time frame: From the date of surgery through 12±2 days after surgery.

Secondary outcomes

  1. Incidence of major VTE

    Defined as objectively confirmed symptomatic DVT and PE, asymptomatic proximal DVT (confirmed by venogram), fatal PE, and unexplained death for which PE cannot be excluded.

    Time frame: From the date of surgery through 12±2 days after surgery and Day 64, respectively.

  2. Incidence of total VTE events

    Defined as symptomatic DVT, asymptomatic DVT (confirmed by venogram), non-fatal and fatal PE, unexplained death for which PE cannot be excluded.

    Time frame: From the date of surgery through Day 64.

  3. Incidence of total VTE events for each individual dosing cohort of SRSD107 compared to enoxaparin

    Defined as symptomatic DVT, asymptomatic DVT (confirmed by venogram), non-fatal and fatal PE, unexplained death for which PE cannot be excluded.

    Time frame: From the date of surgery through 12±2 days after surgery.

  4. Incidence of composite of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB)

    Based on the 2013 Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery (EMA/CHMP/325170/2012), as well as updated guidance from the International Society of Thrombosis and Haemostasis (ISTH; Schulman 2010).

    Time frame: From the Pre-surgical Period through 12±2 days after surgery.

  5. Incidence of composite of MB, CRNMB, and any bleeding

    Based on the 2013 Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery (EMA/CHMP/325170/2012), as well as updated guidance from the International Society of Thrombosis and Haemostasis (ISTH; Schulman 2010).

    Time frame: From the Pre-surgical Period through 12±2 days after surgery, Day 64, and Day 169, respectively.

  6. Incidence of MB

    Based on the 2013 Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery (EMA/CHMP/325170/2012), as well as updated guidance from the International Society of Thrombosis and Haemostasis (ISTH; Schulman 2010).

    Time frame: From the Pre-surgical Period through 12±2 days after surgery.

  7. Incidence of CRNMB

    Based on the 2013 Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery (EMA/CHMP/325170/2012), as well as updated guidance from the International Society of Thrombosis and Haemostasis (ISTH; Schulman 2010).

    Time frame: From the Pre-surgical Period through 12±2 days after surgery.

  8. Incidence of adverse events (AEs)

    An adverse event (AE) is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: From Day 1 through Day 169.

07

Study locations

1 of 1 sites recruiting
  • Hospital Nové Město na Moravě
    Nové Město na Moravě, Czechia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.

Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 24, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Oct 31, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140523
Lead sponsor
Sirius Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Sep 16, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRSD107

Start the discussion